Dr. Gerard Morton, MD, FRCPC
Claim this profileSunnybrook Health Sciences Centre, Odette Cancer Centre
Studies Prostate Cancer
Studies Recurrence
6 reported clinical trials
8 drugs studied
Area of expertise
1Prostate Cancer
Stage III
Stage I
Stage II
2Recurrence
Affiliated Hospitals
Clinical Trials Gerard Morton, MD, FRCPC is currently running
Rectal Hydrogel Spacer
for Prostate Cancer
There are several single institutional series that have reported their experience with salvage radiotherapy options that include EBRT, LDR and HDR brachytherapy. Gastrointestinal (GI) toxicity with salvage radiotherapy range between14-58%, respectively for patients undergoing re-irradiation. There is a concern for an increased risk of fistula development in these patients who receive second course of radiation. Hypofractionation using SABR has been utilized in the re-irradiation setting for prostate cancer with good tumor control and toxicity outcomes. In order to decrease the rectal toxicity, dose to the rectum should be kept as low as possible. Several techniques can be used to achieve this: tighter dosimetric dose painting, better patient or organ immobilization or use of a biodegradable gel. The Investigators ropose a phase I study to assess placement of a hydrogel spacer between the prostate and rectum, in an effort to decrease toxicity and improve patient's bowel quality of life.
Recruiting1 award N/A
SBRT vs. Conventional Radiation
for Prostate Cancer
This trial compares two types of radiation treatments for men with prostate cancer. It aims to see if a shorter, intense treatment is as effective as a longer one. Both treatments use high doses of radiation to kill cancer cells. The modern technique delivers high doses in fewer sessions, showing promise in terms of safety, effectiveness, and cost.
Recruiting1 award N/A5 criteria
More about Gerard Morton, MD, FRCPC
Clinical Trial Related6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Gerard Morton, MD, FRCPC has experience with
- Focal Salvage HDR Brachytherapy
- SABR
- HDR Brachytherapy
- SpaceOAR
- Low Dose Rate Brachytherapy
- High Dose Rate Brachytherapy
Breakdown of trials Gerard Morton, MD, FRCPC has run
Prostate Cancer
Recurrence
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gerard Morton, MD, FRCPC specialize in?
Gerard Morton, MD, FRCPC focuses on Prostate Cancer and Recurrence. In particular, much of their work with Prostate Cancer has involved Stage III patients, or patients who are Stage I.
Is Gerard Morton, MD, FRCPC currently recruiting for clinical trials?
Yes, Gerard Morton, MD, FRCPC is currently recruiting for 3 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Gerard Morton, MD, FRCPC has studied deeply?
Yes, Gerard Morton, MD, FRCPC has studied treatments such as Focal Salvage HDR Brachytherapy, SABR, HDR brachytherapy.
What is the best way to schedule an appointment with Gerard Morton, MD, FRCPC?
Apply for one of the trials that Gerard Morton, MD, FRCPC is conducting.
What is the office address of Gerard Morton, MD, FRCPC?
The office of Gerard Morton, MD, FRCPC is located at: Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, Ontario M4N 3M5 Canada. This is the address for their practice at the Sunnybrook Health Sciences Centre, Odette Cancer Centre.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.